Gruss & Co’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Gruss & Co’s Portfolio BIVV Stock Details BIVV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-1,125	Closed	-$61.3K	–	43
2017 Q1	$61.3K	Buy	+1,125	New	+$55.4K	0.06%	41

Other funds holding BIVV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

ValueAct Holdings San Francisco, California $5.71B AUM 7.41% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Gruss & Co's BIVV Position: Q2 2017 in Review

Gruss & Co sold out of Bioverativ Inc. Common Stock (BIVV) in Q2 2017, closing a stake of 1,125 shares — an estimated $61.3K sold.

Gruss & Co first reported a position in BIVV in Q1 2017 and held it in 1 quarter. The position peaked at $61.3K in Q1 2017. 452 funds tracked by Wall St. Rank hold BIVV as of Q2 2017.

Gruss & Co reported no remaining Bioverativ Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
Gruss & Co sold 1,125 Bioverativ Inc. Common Stock shares in Q2 2017, an estimated $61.3K.
Gruss & Co first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 1 quarter.
Gruss & Co's Bioverativ Inc. Common Stock position peaked at $61.3K in Q1 2017.
452 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q2 2017.

Based on Gruss & Co's 13F filing for Q2 2017, filed 4 Aug 2017.